BUZZ-Jefferies cuts Exact Sciences to 'hold' after Abbott acquisition

Reuters11-24
BUZZ-Jefferies cuts Exact Sciences to 'hold' after Abbott acquisition

** Jefferies downgrades cancer test maker Exact Sciences <EXAS.O> to "hold" from "buy"; raises PT to $105 from $90, a 4.1% upside on the stock's last close

** Brokerage sees limited upside because the stock will likely trade near the deal price following medical device maker Abbott Laboratories' <ABT.N> $23 billion deal

** Jefferies says the acquisition premium is considered fair and attractive for EXAS shareholders and analysts do not expect another bidder to join the race

** The deal is expected to close in the second quarter of 2026

** Nine of 23 brokerages rate stock "buy" or higher, 14 "hold"; their median PT is $105 - data compiled by LSEG

** As of last close, EXAS stock is up ~79.6 YTD

(Reporting by Anuj T in Bengaluru)

((anuj.t@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment